Transcription of Draft Note Guidance Investigation Bioavailability ...
{{id}} {{{paragraph}}}
Example: barber
Draft Note Guidance Investigation Bioavailability ...
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 14 December 2000. CPMP/EWP/QWP/1401/98. COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS. (CPMP). NOTE FOR Guidance ON. THE Investigation OF Bioavailability AND. BIOEQUIVALENCE. DISCUSSION IN THE JOINT EFFICACY AND QUALITY December 1997- WORKING GROUP October 1998. TRANSMISSION TO THE CPMP July 1998. release FOR CONSULTATION December 1998. DEADLINE FOR COMMENTS June 1999. DISCUSSION IN THE DRAFTING GROUP February May 2000. TRANSMISSION TO THE CPMP July - December 2000. release FOR CONSULTATION December 2000. DEADLINE FOR COMMENTS March 2001. Note: This revised Note for Guidance will replace the previous guideline adopted in December 1991. Any comments should be sent to the EMEA, EWP Secretariat (Fax No. 44-20-74188613).
5.1.3.Non-Oral Immediate Release forms with systemic action 13 5.1.4.Modified Release and transdermal dosage forms 13 5.1.5.Fixed combinations products 13 5.1.6.Parenteral solutions 13 5.1.7.Gases 13 5.1.8.Locally applied products 13 5.2. In Vitro Dissolution 14 5.3. Variations 14 5.4. Dose proportionality in immediate release oral dosage forms ...
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: